METTL3‐mediated m6A mRNA contributes to the resistance of carbon‐ion radiotherapy in non‐small‐cell lung cancer

Lung cancer is one of the leading causes of death among cancer patients worldwide. Carbon‐ion radiotherapy is a radical nonsurgical treatment with high local control rates and no serious adverse events. N6‐methyladenosine (m6A) modification is one of the most common chemical modifications in eukaryotic messenger RNA (mRNA) and has important effects on the stability, splicing, and translation of mRNAs. Recently, the regulatory role of m6A in tumorigenesis has been recognized more and more. However, the dysregulation of m6A and its role in carbon‐ion radiotherapy of non‐small‐cell lung cancer (NSCLC) remains unclear. In this study, we found that the level of methyltransferase‐like 3 (METTL3) and its mediated m6A modification were elevated in NSCLC cells with carbon‐ion radiotherapy. Knockdown of METTL3 in NSCLC cells impaired proliferation, migration, and invasion in vitro and in vivo. Moreover, we found that METTL3‐mediated m6A modification of mRNA inhibited the decay of H2A histone family member X (H2AX) mRNA and enhanced its expression, which led to enhanced DNA damage repair and cell survival.

[1]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[2]  A. Monteiro,et al.  DNA damage response and repair in perspective: Aedes aegypti, Drosophila melanogaster and Homo sapiens , 2019, Parasites & Vectors.

[3]  Jingfang Zhao,et al.  Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. , 2019, Annals of translational medicine.

[4]  K. Shirai,et al.  Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer , 2019, Front. Oncol..

[5]  Yi Han,et al.  The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. , 2019, Biochemical and biophysical research communications.

[6]  Lijia Ma,et al.  Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation , 2019, Nature Communications.

[7]  Hui Shen,et al.  m6A Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2 , 2019, Genom. Proteom. Bioinform..

[8]  Zhiyong Zhang,et al.  METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes , 2019, Autophagy.

[9]  S. Ji,et al.  The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression , 2019, Nucleic acids research.

[10]  K. Ogawa,et al.  Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer , 2019, Cancer science.

[11]  J. Hanna,et al.  m6A modification controls the innate immune response to infection by targeting type I interferons , 2018, Nature Immunology.

[12]  Michaela Frye,et al.  RNA modifications modulate gene expression during development , 2018, Science.

[13]  R. Hajjar,et al.  FTO-Dependent N6-Methyladenosine Regulates Cardiac Function During Remodeling and Repair , 2018, Circulation.

[14]  K. Ogawa,et al.  Feasibility of carbon‐ion radiotherapy for re‐irradiation of locoregionally recurrent, metastatic, or secondary lung tumors , 2018, Cancer science.

[15]  Zhike Lu,et al.  m6A facilitates hippocampus-dependent learning and memory through Ythdf1 , 2018, Nature.

[16]  P. Ma,et al.  Multiple functions of m6A RNA methylation in cancer , 2018, Journal of Hematology & Oncology.

[17]  Astrid Zimmermann,et al.  Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation , 2017, Radiation Oncology.

[18]  Yue Sheng,et al.  METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. , 2017, Cell stem cell.

[19]  T. Fujisawa,et al.  Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis , 2017, Radiation oncology.

[20]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[21]  Douglas L Black,et al.  m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover , 2017, Genes & development.

[22]  Yu-Ling Wu,et al.  Mesenchymal stem cell‐derived CCN2 promotes the proliferation, migration and invasion of human tongue squamous cell carcinoma cells , 2017, Cancer science.

[23]  C. Redon,et al.  H2AX and EMT: deciphering beyond DNA repair , 2016, Cell cycle.

[24]  B. Tang,et al.  The interplay between DNA repair and autophagy in cancer therapy , 2015, Cancer biology & therapy.

[25]  H. Iwata,et al.  Carbon Ion Therapy for Early-Stage Non-Small-Cell Lung Cancer , 2014, BioMed research international.

[26]  Samir Adhikari,et al.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase , 2014, Cell Research.

[27]  R. Scully,et al.  Double strand break repair functions of histone H2AX. , 2013, Mutation research.

[28]  H. Tsujii,et al.  Carbon Ion Radiotherapy for Oligo-Recurrence in the Lung , 2013, Pulmonary medicine.

[29]  M. Kupiec,et al.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq , 2012, Nature.

[30]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[31]  Yuta Shibamoto,et al.  High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancer , 2010, Cancer.

[32]  George Iliakis,et al.  γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin , 2008, Nucleic acids research.

[33]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[34]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.